Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins

Japanese Journal of Infectious Diseases

Volumn 53, Issue 6, 2000, Pages 219-228

  Chen, Ze ^a   Kurata, Takeshi ^b   Tamura, Shin Ichi ^b  

^a HUNAN NORMAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; PLASMID DNA; SIALIDASE; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; GENE EXPRESSION; GENETIC HETEROGENEITY; IMMUNIZATION; INFLUENZA VIRUS; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MOUSE; MOUSE STRAIN; NONHUMAN; PROTECTION; REVIEW;

ANIMALS; HEMAGGLUTININS; IMMUNIZATION; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEURAMINIDASE; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PLASMIDS; VACCINES, DNA; VIRAL PROTEINS;

EID: 0034458639     PISSN: 13446304     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Structural basis of immune recognition of influenza virus hemagglutinin
2. Immunity to influenza in man
3. Review of existing vaccines for influenza
4. Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans
5. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response
6. Immunization with influenza A virus hemagglutinin and neuraminidase produced in recombinant baculovirus results in a balanced and broadened immune response superior to conventional vaccine
7. Association of serum anti-neuraminidase antibody with resistance to influenza in man
8. Induction of partial immunity to influenza by a neuraminidase-specific vaccine
9. Comparative efficacy of neuraminidase-specific and comventional influenza virus vaccines in induction of antibody to neuraminidase in humans
10. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans
11. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees
12. Comparative long-term effects in a mouse model system of influenza whole virus and purified neuraminidase vaccines followed by sequential infections
13. Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults
14. Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions
15. Antiviral activity of antiserum specific for an influenza virus neuraminidase
16. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice
17. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection
18. Antigen-presenting B cells and T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins
19. Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience
20. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravironic antigenic competion
21. Immunization with purified N1 and N2 influenza virus neuraminidases demonstrates cross-reactivity without antigenic competition
22. Immunization with dissociated neuraminidase, matrix, and nucleonproteins from influenza A virus eliminates cognate help and antigenic competition
23. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins
24. Gene vaccination: Plasmid DNA is more than just a blueprint
25. Heterologous protection against influenza by injection of DNA encoding a viral protein
26. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA
27. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines
28. Protection of ferrests against influenza challenge with a DNA vaccine to the haemagglutinin
29. DNA immunization for influenza virus: Studies using hemagglutinin-and nucleoprotein-expressing DNAs
30. Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine
31. Cross-protection among lethal H5N2 influenza viruses induced by DNA vaccine to the hemagglutinin
32. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice
33. Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization
34. Excess mortality from epidemic influenza, 1957-1966
35. Serologic responses and systemic reactions in adults after vaccination with bivalent A/Victoria/75-A/New Jersey/76 and monovalent B/Hong Kong/72 influenza vaccines
36. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children
37. The Seattle virus watch. IV. Comparative epidemiologic observations of infections with influenza A and B viruses, 1965-1969, in families with young children
38. The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966-1971
39. Influenza A and B virus infection in infants and young children during the years 1957-1976
40. Severe illness with influenza B
41. Morbidity and mortality associated with influenza B in the United States, 1979-1980. A report from the Center for Disease Control
42. Viral and idiopathic myocarditis in Japan: A questionnaire survey
43. A nationwide outbreak of Reye's Syndrome. Its epidemiologic relationship of influenza B
44. Beta 2-immunoglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase
45. A universal influenza A vaccine based on the extracellular domain of the M2 protein
46. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza
47. Efficient selection for high-expression transfectants with a novel eukaryotic vector
48. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different haemagglutinin molecules
49. + T cells
50. Protection against influenza B virus infection by immunization with DNA vaccines
51. Gene transfer into muscle by electroporation in vivo
52. Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation
53. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin-and neuraminidase-expressing DNAs
54. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase
55. The H-2 majority histocompatibility complex and the I immune response region: Genetic variation, function, and organization
56. H-2-unrestricted adjuvant effect of cholera toxin B subunit on murine antibody response to influenza virus haemagglutinin
57. DNA vaccine
58. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors
59. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein
60. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell activity
61. Immunity to infection on secretory surfaces
62. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit
63. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine
64. Synergistic action of cholera toxin B subunit (and E. coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine
65. Escherichia coli heat labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine
66. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza HA vaccine
67. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit